Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  2008-11-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14712590802528696PMID 18990079
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

  2008cited by this paper
• Inhibition of IκB Kinase Subunit 2 in Cutaneous T-Cell Lymphoma Down-Regulates Nuclear Factor-κB Constitutive Activation, Induces Cell Death, and Potentiates the Apoptotic Response to Antineoplastic Chemotherapeutic Agents

  2008cited by this paper
• Short German guidelines: Cutaneous lymphomas

  2008cited by this paper
• Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma: Results of a Phase II Study.

  2007cited by this paper
• Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study.

  2007cited by this paper
• Development of histone deacetylase inhibitors for cancer treatment

  2007cited by this paper
• Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.

  2007cited by this paper
• In situ depletion of CD4+ T cells in human skin by Zanolimumab

  2007cited by this paper
• Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

  2007cited by this paper
• Efficacy and safety of denileukin diftitox (Dd) in a phase III, double-blind, placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma (CTCL)

  2007cited by this paper
• Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma

  2007cited by this paper
• Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.

  2007cited by this paper
• Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.

  2007cited by this paper
• Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).

  2007cited by this paper
• Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphoma

  2007cited by this paper
• Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.

  2007cited by this paper
• A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity.

  2007influential reference
• Histone deacetylase inhibitors in cancer therapy

  2007cited by this paper
• EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.

  2006cited by this paper
• Significant impact of cutaneous T‐cell lymphoma on patients' quality of life

  2006cited by this paper
• LBH589, a Novel Deacetylase Inhibitor (DACi), Treatment of Patients with Cutaneous T-Cell Lymphoma (CTCL). Skin Gene Expression Profiles in the First 24 Hours Related to Clinical Response Following Therapy.

  2006cited by this paper
• Zanolimumab, a Fully Human Monoclonal Antibody: Early Results of an Ongoing Clinical Trial in Patients with CD4+ Mycosis Fungoides (MF) Type CTCL (Stage IB-IVB) Who Are Refractory or Intolerant to Targretin and One Other Standard Therapy.

  2006cited by this paper
• Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab *

  2006cited by this paper
• Histone Deacetylase Inhibitors for Cancer Therapy

  2006cited by this paper
• Traitements locaux des lymphomes T cutanés

  2005cited by this paper
• Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.

  2005cited by this paper
• No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.

  2005cited by this paper
• Proteasome inhibitor therapy in multiple myeloma

  2005cited by this paper
• A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.

  2005cited by this paper
• [Therapy algorithm for cutaneous T-cell lymphomas].

  2005cited by this paper
• C66 - Étude de polymorphismes des gènes dcp1 et b2bkr dans les vasculites cutanées

  2005cited by this paper
• Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma

  2005cited by this paper
• The pathogenesis of mycosis fungoides.

  2004cited by this paper
• Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II.

  2004cited by this paper
• Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.

  2004cited by this paper
• Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T‐cell lymphoma

  2003cited by this paper
• HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.

  2003cited by this paper
• Adaptor proteins in lymphocyte activation.

  2003influential reference
• Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab

  2003cited by this paper
• Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.

  2003cited by this paper
• Topical carmustine (BCNU) in the treatment of mycosis fungoides

  2003cited by this paper
• Protein kinase B (Akt) regulation and function in T lymphocytes.

  2002cited by this paper
• Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.

  2002cited by this paper
• Ligation of human CD4 interferes with antigen-induced activation of primary T cells.

  2002cited by this paper
• Akt-Dependent Phosphorylation Specifically Regulates Cot Induction of NF-κB-Dependent Transcription

  2002cited by this paper
• Alemtuzumab in T-cell malignancies

  2002influential reference
• Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

  2001cited by this paper
• Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.

  2001cited by this paper
• Histone acetylation and disease

  2001cited by this paper
• Treatment of erythrodermic cutaneous T‐cell lymphoma with intermittent chlorambucil and fluocortolone therapy

  2000cited by this paper
• Primary cutaneous T-cell lymphoma: review and current concepts.

  2000cited by this paper
• Primary cutaneous B-cell lymphoma: review and current concepts.

  2000cited by this paper
• Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T‐cell lymphoma

  1999cited by this paper
• Differential effects of administration of a human anti-CD4 monoclonal antibody, HM6G, in nonhuman primates.

  1999cited by this paper
• Cross‐linking of the CAMPATH‐1 antigen (CD52) mediates growth inhibition in human B‐ and T‐lymphoma cell lines, and subsequent emergence of CD52‐deficient cells

  1998cited by this paper
• Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.

  1998cited by this paper
• Topical corticosteroids for mycosis fungoides. Experience in 79 patients.

  1998cited by this paper
• Signalling through the lipid products of phosphoinositide-3-OH kinase

  1997cited by this paper
• Proceedings of the International Consensus Conference on Cutaneous T-cell Lymphoma (CTCL) Treatment Recommendations. Boston, Massachusetts, Oct. 1 and 2, 1994.

  1997cited by this paper
• Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma.

  1997cited by this paper
• High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.

  1996cited by this paper
• High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice

  1996cited by this paper
• Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.

  1996cited by this paper
• The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase.

  1996cited by this paper
• Interferon in the treatment of cutaneous T-cell lymphoma.

  1995cited by this paper
• Interferon treatment of cutaneous T‐cell lymphoma

  1993influential reference
• Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma.

  1992cited by this paper
• Signal transduction through the CD4 receptor involves the activation of the internal membrane tyrosine-protein kinase p56lck

  1989influential reference
• A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides.

  1989cited by this paper
• Topical mechlorethamine therapy for early stage mycosis fungoides.

  1988cited by this paper

• Unveiling the Role of the Cellular Tumor Microenvironment and the Therapeutic Targets it Provides in Cutaneous T-Cell Lymphoma

  2025cites this paper
• Monoclonal antibody‐mediated immunosuppression enables long‐term survival of transplanted human neural stem cells in mouse brain

  2022cites this paper
• Monoclonal antibodies used for the management of hemataological disorders

  2022cites this paper
• The Evolution of Molecular Recognition: From Antibodies to Molecularly Imprinted Polymers (MIPs) as Artificial Counterpart

  2022cites this paper
• Monoclonal antibodies used for management of hematological disorders

  2021cites this paper
• Innovative Behandlungskonzepte mit Modulation der Mikroumgebung beim kutanen T-Zell-Lymphom

  2019cites this paper
• Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation

  2017cites this paper
• Monoclonal antibodies against cutaneous T-cell lymphomas

  2017cites this paper
• Monoclonal Antibodies.

  2015cites this paper
• Current Management and Treatment of T-cell Lymphoma : A Multidisciplinary Approach

  2013cites this paper
• New Monoclonal Antibodies for Indolent Non-Hodgkin Lymphoma

  2013cites this paper
• Mycosis fungoïde et syndrome de Sézary Mycosis fungoïdes and Sézary syndrome

  2012cites this paper
• Recent advances in the management of cutaneous lymphomas.

  2012cites this paper
• New drug therapies in peripheral T-cell lymphoma

  2011cites this paper
• Have we overestimated the benefit of human(ized) antibodies?

  2010cites this paper
• Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies.

  2010cites this paper
• Treatment of cutaneous lymphomas: today and tomorrow.

  2009cites this paper
• Monoclonal antibody therapy of T cell lymphoma: single agent trials of anti-CD2 (Siplizumab) and anti-CD4 (Humax-CD4)

  2009cites this paper